Successful treatment of a patient with myelodysplastic syndrome (RAEB) with Darbepoetin-alfa in combination with Pegfilgrastim [4]

Annals of Hematology

Volumn 84, Issue 10, 2005, Pages 694-695

  Jakob, Andreas ^a   Hirsch, Friedrich W ^a   Engelhardt, Monika ^b  

^a OFFENBURG UNIVERSITY OF APPLIED SCIENCES   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYANOCOBALAMIN; CYCLOSPORIN A; ERYTHROPOIETIN; FOLIC ACID; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE;

AGED; BONE MARROW BIOPSY; CANCER GROWTH; CASE REPORT; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; HUMAN CELL; LETTER; LEUKOCYTE COUNT; MALE; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; REFRACTORY ANEMIA WITH EXCESS BLASTS; SEPSIS; THROMBOCYTE COUNT; TREATMENT FAILURE; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

AGED; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN; FILGRASTIM; HUMANS; LEUKOCYTE COUNT; MALE;

EID: 27644500485     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-1060-2     Document Type: Letter

References (10)

1. Casadevall N, Durieux P, Dubois S et al (2004) Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: A randomized, controlled trial. Blood 104:321-327 10.1182/ blood-2003-07-2252
2. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G et al (2003) A validated decision model for treating the anemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: Significant effects on quality of life. Br J Haematol 120:1037-1046 10.1046/ j.1365-2141.2003.04153.x
3. Seipelt et al (2000) Cytokine therapy for myelodysplastic syndrome. Curr Opin Hematol 7:156-160 10.1097/00062752-200005000-00005
4. Kasper C, Zahner J, Sayer HG (2002) Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. J Cancer Res Clin Oncol 128:497-502
5. Musto P, Sanpaolo G, D'Arena G et al (2001) Adding growth factors or IL-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone. Haematologica 86:44-51 1:CAS:528:DC%2BD3MXhsFGksb8%3D
6. Tehranchi R, Fadeel B, Forsblom AM et al (2003) Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood 101:1080-1086 10.1182/blood-2002-06-1774
7. Rigolin GM, Porta MD, Ciccone M et al (2004) In patients with myelodysplastic syndromes response to rhEPO and G-CSF treatment is related to an increase of cytogenetically normal CD34 cells. Br J Haematol 126:501-507 10.1111/j.1365-2141.2004.05086.x
8. Cheson BD, Bennett JM, Kantarjian H et al (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671-3674 1:CAS:528:DC%2BD3cXosVGnt7o%3D
9. Musto P, Lanza F, Balleari E et al (2004) Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 128:204-209 10.1111/j.1365-2141.2004.05288.x
10. Spiriti MAA, Latagliata R, Niscola P et al (2005) Impact of a new dosing regimen of epoetin alfa on quality of life an anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol 84:167-176 10.1007/ s00277-004-0961-9